Optimization of PSMA-I&T radiolabeling with 177Lu

Optimization of PSMA-I&T radiolabeling with 177Lu

Prostate cancer (PCa) is the second most common type of cancer in men and the fifth cause of mortality worldwide. Metastatic prostate cancer is associated with a poor prognosis and decreased life expectancy. Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Luiza Mascarenhas Balieiro, Maria das Dores Domingos, Luana Pereira da Silva, Joel Mendes dos Santos, Margareth Mie Nakamura Matsuda, Luis Alberto Pereira Dias, Elaine Bortoleti de Araújo
Format:	Article
Language:	English
Published:	Brazilian Radiation Protection Society (Sociedade Brasileira de Proteção Radiológica, SBPR) 2025-06-01
Series:	Brazilian Journal of Radiation Sciences
Subjects:	Radiolabeling 1 PSMA I&T 2 Optimization 3 Lutetium-177 4
Online Access:	https://bjrs.org.br/revista/index.php/REVISTA/article/view/2690
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01)

Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters
by: William Hunt, et al.
Published: (2025-07-01)

177Lu‐Gold Nanohybrids in Radiotherapeutic Approaches Against Cancer
by: Mathilde Ponchelle, et al.
Published: (2025-05-01)

Hematological toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS syngeneic mouse model
by: Meryl Maria Vilangattil, et al.
Published: (2025-03-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Very good effect of rescue treatment with 177Lu-DOTATATE in the patient with advanced metastatic atypical lung carcinoid
by: Małgorzata Elżbieta Poniatowska, et al.
Published: (2025-01-01)

Comparison of tumour segmentation methods for dosimetry in [177Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer
by: Peter Frøhlich Staanum, et al.
Published: (2025-07-01)

Optimizing Standardization Systems and Standardizing Clinical Practice: Interpretation of Quality Standards for Medical 68Ge/68Ga Generators and 68Ga Radiopharmaceuticals and Quality Standards for Medical 177Lu and Its Radiopharmaceuticals
by: LAI Yuxin, et al.
Published: (2025-07-01)

Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer
by: Hugo Peslier, et al.
Published: (2025-03-01)

Bias and precision of SPECT-based 177Lu activity-concentration estimation using a ring-configured solid-state versus a dual-headed anger system
by: Anna Stenvall, et al.
Published: (2024-11-01)

Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022
by: D. A. Andreev, et al.
Published: (2022-06-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

On the feasibility of producing Lu-177 in the IEA-R1 reactor via the direct route
by: Guilherme Soares Zahn, et al.
Published: (2021-04-01)

Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications
by: Andrés Núñez-Salinas, et al.
Published: (2025-07-01)

3D-Printed Organ-Realistic Phantoms to Verify Quantitative SPECT/CT Accuracy for 177Lu-PSMA-617 Treatment Planning
by: Lydia J. Wilson, et al.
Published: (2025-04-01)

Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
by: Hyunpil Sung, et al.
Published: (2025-08-01)

RM2 and DB15 analogues bearing [177Lu]Lu-DOTAGA via different linkers, as radiotherapeutics: a head-to-head comparative study
by: Panagiotis Kanellopoulos, et al.
Published: (2025-07-01)

Toward the standardization of radiopharmaceutical therapies: a technical note evaluating a clinical dosimetry workflow for single-time-point 177Lu SPECT/CT-based therapies
by: Taehyung Peter Kim, et al.
Published: (2025-08-01)

First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myeloma
by: Wendy Delbart, et al.
Published: (2025-07-01)

Centrifuge-free cell radiolabeling using acoustophoresis
by: Stephen S. Adler, et al.
Published: (2025-07-01)

Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy
by: Felix L. Herr, et al.
Published: (2025-08-01)

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01)

[225Ac]Ac-PSMA-617 production method: development of an efficient and reproducible radiolabelling process for establish a clinical routine production
by: Michela Aurilio, et al.
Published: (2025-05-01)

Metastatic Bone Pain Palliation using 177 Lu-Ethylenediaminetetramethylene Phosphonic Acid
by: Mehrosadat Alavi, et al.
Published: (2015-04-01)

Application of 68Ga‐ and 177Lu‐Labeled FAP Inhibitor in Evaluation and Treatment of Cardiac Fibrosis After Myocardial Infarction
by: Yiheng Zhao, et al.
Published: (2025-06-01)

PSMA PET/CT scan reveals incidental meningioma in a prostate cancer patient
by: Venetia A. Florou, et al.
Published: (2025-05-01)

Visualization of the Spiral Ganglion Neuron in Vivo Using a Novel 177Lu Nuclear Molecule Label
by: Chenyang Kong, et al.
Published: (2025-08-01)

Evaluation of using small volume of interest regions for clinical kidney dosimetry in 177Lu-DOTATATE treatments
by: Jehangir Khan, et al.
Published: (2025-07-01)

Dose-Dependent Cellular Phenotypic Change Induced by <sup>177</sup>Lu-Oxodotreotide Treatment in IMR-32 Cells
by: Shuai Xue, et al.
Published: (2025-06-01)

PSMA5 as a modulator of glioblastoma senescence and prognosis
by: Jiahao Yao, et al.
Published: (2025-07-01)

Specific reaction conditions for efficient automated 68Ga-radiolabeling of the FAP-2286 pseudopeptide on a GAIA® synthesizer
by: Maissa Ammour, et al.
Published: (2025-07-01)

Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11
by: Jianpeng Cao, et al.
Published: (2025-06-01)

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome
by: Chinna Naik, et al.
Published: (2017-04-01)

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)

Rapid cleavage of 6-[18F]fluoronicotinic acid prosthetic group governs BT12 glioblastoma xenograft uptake: implications for radiolabeling design of biomolecules
by: Pyry Dillemuth, et al.
Published: (2025-07-01)

Evaluation the Electronic Properties of Glu-Ureido Template via Ab-Initio Study as Target Specific for PSMA
by: Mohd. Faheem, et al.
Published: (2024-11-01)

Somatostatin-receptor avidity of pancreatic neuroendocrine tumor thrombus in porto-caval venous systems on 99mTc-Octreotide and posttherapeutic 177Lu-DOTA-TATE scans
by: Mahasti Amoui, et al.
Published: (2021-07-01)

AI based automatic measurement of split renal function in [18F]PSMA-1007 PET/CT
by: Kristian Valind, et al.
Published: (2025-06-01)

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
by: Latifa Zekri, et al.
Published: (2020-12-01)

Automated fluorine-18 radiolabeling via an alkyne–azide cycloaddition reaction on a dual peptide-functionalized liposome surface for in vivo PET imaging
by: Marco Iannone, et al.
Published: (2025-04-01)